# REVIEW

# **Open Access**

# Postoperative complications and prognosis after radical gastrectomy for gastric cancer: a systematic review and meta-analysis of observational studies



Shiqi Wang<sup>1\*†</sup>, Lei Xu<sup>2†</sup>, Quan Wang<sup>1†</sup>, Jipeng Li<sup>1</sup>, Bin Bai<sup>1</sup>, Zhengyan Li<sup>1</sup>, Xiaoyong Wu<sup>1</sup>, Pengfei Yu<sup>1</sup>, Xuzhao Li<sup>1</sup> and Jichao Yin<sup>2\*</sup>

# Abstract

**Background:** Many observational studies have reported correlations between postoperative complications and prognosis after radical gastrectomy but the results are controversial. This meta-analysis was performed to investigate whether there is a correlation between postoperative complications and prognosis after radical gastrectomy.

**Methods:** Literature searches were performed in PubMed, EMBASE, and the Cochrane Library. Studies that investigated the correlations between any postoperative complications and prognosis after radical gastrectomy were included. The pooled hazard ratio (HR) with 95% confidence interval (CI) for postoperative complications regarding overall survival (OS) or recurrence-free survival (RFS) was calculated by using RevMan 5.3.5. Subgroup analyses were performed within pathological stages I, II, and III.

**Results:** Sixteen retrospective studies comprising 12,065 patients were included. The pooled HR (95% CI) for complications regarding OS was 1.79 (1.39, 2.30) and was 1.40 (1.06, 1.84) after excluding in-hospital mortality; the pooled HR (95% CI) for complications regarding RFS was 1.28 (1.10, 1.49). The pooled HR (95% CI) for infectious complications and leakage regarding OS was 1.86 (1.22, 2.83) and 2.02 (1.02, 4.00), respectively. The pooled HR (95% CI) for any reported postoperative complications regarding OS for stage I, II, and III diseases was 2.39 (0.77, 7.46), 4.35 (2.58, 7.35), and 2.84 (1.77, 4.56), respectively.

**Conclusions:** Postoperative complications correlate with poor prognosis after radical gastrectomy. Such correlations are found in stage II and III gastric cancer patients but remain to be determined in stage I gastric cancer patients.

Keywords: Complications, Prognosis, Radical gastrectomy, Stomach neoplasms

# Background

The incidence of postoperative complications after radical gastrectomy remains high [1-4], and the estimated incidence is 12.8 to 14% [5–7]. In addition to undermining the short-term survival, postoperative complications may also be correlated with long term prognosis. Currently, increasing numbers of observational studies have

\* Correspondence: wsqfmmu@126.com; 83797727@163.com

<sup>1</sup>Shiqi Wang, Lei Xu, and Quan Wang contributed equally to this work. <sup>1</sup>Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Changlexi St. 127#, Xi'An City, Shaanxi Province, China investigated the correlation between postoperative complications and long-term prognosis after radical gastrectomy. Although some reports have negative findings [8–12], other studies have demonstrated that overall postoperative complications, infectious complications, and gastrointestinal leakages are all correlated with poor overall survival (OS) and/or recurrence-free survival (RFS) [13–23]. Additionally, the correlations between postoperative complications and long-term prognosis in different stages are controversial and are based on subgroup analyses with small sample sizes [13, 18–20].



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

 <sup>&</sup>lt;sup>2</sup>Xi'an Hospital of Traditional Chinese Medicine, Fengcheng 8th St. 69#, Xi'An City, Shaanxi Province, China

Given the prevalence of postoperative complications after radical gastrectomy, it is important to determine whether a correlation exists between postoperative complications and poor prognosis. The existence of that correlation may not only lead to a consideration of shortening follow-up interval and enforcing adjuvant chemotherapy in patient who have developed postoperative complications, but may also underline the necessity of neoadjuvant chemotherapy and stress control management in patients with high risk of developing postoperative complications to reduce the hazard for long term prognosis [9, 11, 21]. In the meta-analysis, the correlations between postoperative complications and prognosis after radical gastrectomy were assessed.

# Methods

# Search strategy and eligibility criteria

The PubMed, EMBASE, and Cochrane Library databases were searched from inception until February 24, 2019, for studies that assessed the relationship between postoperative complications and prognosis after radical gastrectomy. The following medical subject heading (MeSH) terms and keywords were used: "Stomach Neoplasms", "Gastrectomy", "Postoperative Complications", and "Prognosis". The search was restricted to studies on humans and to those that were published in the English language. The titles and abstracts were screened by two authors independently. The inclusion criterion was as follows: any study that compared the long-term prognosis between patients with and without postoperative complications after radical gastrectomy for gastric cancer. The exclusion criteria were as follows: (1) data of other neoplasms other than gastric cancer were included in the survival analysis; (2) data of palliative surgery were included in the survival analysis; (3) studies that describe the same patient population; (4) hazard ratio (HR) cannot be estimated; (5) describing complications without precise definitions; (6) letters, comments, or conference abstracts. When multiple studies describing the same patient population were identified, the most recent publication was used unless additional data were provided in the earlier work.

# Data extraction

The following data were extracted: first author, year of publication, study design, number of subjects, adjuvant chemotherapy, tumor stage, types of complications, incidences of complications, HR of any postoperative complications, and 5-year OS and 5-year RFS for patients with and without postoperative complications, as well as whether in-hospital deaths were excluded in the survival analysis. Unreported data were requested through e-mail from corresponding authors of the included studies. If there was no response to the e-mails, the missing data were estimated from the figures in the published literatures using Engauge Digitizer 4.1 (Mark Mitchell, Baurzhan Muftakhidinov, and Tobias Winchen et al., "Engauge Digitizer Software." Webpage: http://markummitchell.github.io/engauge-digitizer) and the HRs were estimated using the method of Tierney et al. [24].

# Study quality assessment

The methodological quality of each observational study was assessed by the Newcastle-Ottawa Scale (NOS, ranging 0–9) [25]. In brief, each study was assessed for the following aspects: selection, comparability, and outcome or exposure. The comparability was primarily assessed for pathological stage and was also assessed for aspects of adjuvant chemotherapy and in-hospital death disposition in the survival analysis.

# Statistical analysis

Statistical analysis was performed with RevMan (version 5.3.5.; Cochrane Collaboration). HRs and their 95% confidence intervals (CIs) were used to evaluate the association between postoperative complications and prognosis (OS and/or RFS). Subgroup analyses were performed to investigate the correlations between infectious complication, gastrointestinal leakage, and prognosis. Furthermore, correlations were investigated for each pathological stage when possible. Statistical heterogeneities among studies were assessed by the  $I^2$  statistic. The random effects model and the fixed effects model were used. If  $I^2$  was less than 40% (cutoff point), we used the fixed effect model, while if  $I^2$  was more than 40%, the random effects model was chosen. Sensitivity analysis, in which one study was removed at a time, was performed to evaluate the stability of the results. Descriptive techniques were used when clinical heterogeneity existed or when no data could be used in the pooling analysis. The assessment of publication bias was evaluated using the funnel plot.

We followed both the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement [26], and the guidelines for Meta-analysis of Observational Studies in Epidemiology (MOOSE) in reporting this study [27]. All analyses were based on previously published studies, thus no ethical approval and patient consent are required.

# Results

## Literature searches and description of studies

The flow diagram of the literature searches is shown in Fig. 1. The entire study sample size from the 16 included studies was 12,065 patients. The characteristics of the included studies are shown in Table 1. The quality of the included studies was analyzed, and the NOS scores of the included studies varied between 6 and 9 points (see Additional file 1: Table S1).



## Studies on postoperative complications and OS

Thirteen studies were included in the analysis of correlation between any reported postoperative complications and OS [8, 10, 12–19, 21–23]. Of the included studies, eight excluded influences from in-hospital death in the survival analysis [8, 10, 12–14, 19, 21, 23]. The pooled HR (95% CI) of postoperative complications for OS was 1.79 (1.39, 2.30) and was 1.40 (1.06, 1.84) after excluding the in-hospital mortality (Fig. 2). The sensitivity analysis demonstrated that no individual study significantly influenced the overall effect of the HRs. Publication bias was examined by the funnel plot and there was no evidence of publication bias among these comparisons (Fig. 3).

Six studies reported the correlation between infectious complications and OS [8, 10, 13–15, 18]. Four of the studies excluded the in-hospital mortality [8, 10, 13, 14]. The pooled HR of postoperative infectious complications for OS was 1.86 (1.22, 2.83) and was 1.47 (0.90, 2.40) after excluding the in-hospital mortality (Fig. 2). Sensitivity analysis demonstrated that the study form Kim et al. caused high heterogeneity. After excluding the study, the corresponding pooled HR (95% CI) of infectious complications (in-hospital mortality excluded) changed from 1.47 (0.90, 2.40) to 1.77 (1.12, 2.79).

Four studies reported the relationship between gastrointestinal leakages and OS [8, 13–15]. Three studies excluded the in-hospital mortality [8, 13, 14]. The pooled HR of gastrointestinal leakages for OS was 2.02 (1.02, 4.00) and was 1.64 (0.78, 3.46) after excluding the in-hospital mortality (Fig. 2). Sensitivity analysis demonstrated that the study form Kim et al. caused high heterogeneity. After excluding the study, the corresponding pooled HR (95% CI) of leakage (in-hospital mortality excluded) changed from 1.64 (0.78, 3.46) to 2.25 (1.45, 3.47).

# Studies on postoperative complications and RFS

Seven studies were included in the analysis of correlation between any reported postoperative complications and RFS [9–12, 18, 20, 21]. Four studies excluded the in-hospital mortality [10, 11, 20, 21]. The pooled HR for RFS is 1.28 (1.10, 1.49) and was 1.33 (1.09, 1.63) after excluding the in-hospital death (Fig. 4).

Four studies investigated the correlation between infectious complications and RFS [10, 11, 18, 20], and three of them excluded the in-hospital mortality in the

Table 1 Study characteris:	tics									
Author, year	NOS	Country	Sample <sup>a</sup>	Period	Complications	Comparable		In-hospital	5-year RFS <sup>b</sup>	5-year OS <sup>b</sup>
	score		size		type	Pathological stage	Chemotherapy	death		
Tsujimoto et al. 2009 [13]	∞	Japan	141/1191	1986–2005	Infectious	Not	Not*	Excluded	NR	57.9% vs. 78.1%
Sierzega et al. 2010 [14]	7	Poland	41/649	1999–2004	Leakage	NR	NR	Involved	NR	NR
Yoo et al. 2011 [15]	9	Korea	32/446	2000-2005	Leakage	Yes	NR	Involved	NR	9.4% vs. 68.4%
Nagasako et al. 2012 [16]	9	Japan	37/363	1997-2008	Anastomotic	NR	NR	Involved	NR	81% vs. 94.2%
Li et al. 2013 [17]	7	China	51/378	2005-2006	Overall	NR	NR	Involved	NR	21.8%vs. 39.9%
Tokunaga et al. 2013 [18]	Q	Japan	81/684	2002-2006	Intra-abdominal infectious	Not	None	Involved	64.9% vs. 84.5%	66.4% vs. 86.8%
Kubota et al. 2014 [19]	7	Japan	207/981	2005-2008	Overall CD ≥ 2	Not	NR	Excluded	NR	84.1% vs. 93.1%
Hayashi et al. 2015 [ <mark>20</mark> ]	7	Japan	52/450	2000-2005	Infectious CD ≥ 2	Not	None	None	NR	58% vs. 83%
Kim et al. 2015 [ <mark>8</mark> ]	7	Korea	72/3755	2003-2012	Leakage	NR	NR	None	NR	70.8% vs. 79.3%
Saito al. 2015 [9]	9	Japan	86/219	2001-2012	Overall CD ≥ 2	NR	NR	NR	53.4% vs. 70.5%	NR
Jin et al. 2016 [21]	9	U.S.A	336/488	2000-2012	Overall	Not	Not	Excluded	23% vs. 40%	27% vs. 43%
Abdul Kader et al. 2016 [22]	7	Japan	38/227	1991–2010	Intra-abdominal	Yes	Yes	Involved	NR	24.6% vs. 69.2%
Climent et al. 2016 [10]	œ	Spain	162/109	1990–2009	Overall CD $\geq 2/$ infectious	Yes	Yes	Excluded	46.9% vs. 54.1%	48.1% vs. 56.9%
Li et al. 2018 [ <mark>23</mark> ]	00	China	86/172	2008-2015	Overall CD > 2	Yes	NA	Excluded	NA	46.3% vs. 65.9%
Eto et al. 2018 [11]	6	Japan	35/66	2005-2015	Overall CD ≥ 2	Yes	Yes	None	41.7% vs. 43.9%	58.2% vs. 56.3%
Watanabe et al. 2018 [12]	7	Japan	134/296	1992-2010	Overall CD > 2	Not	Yes	Involved	46.9% vs. 45.0%	51.3% vs. 47.6%
<i>CD</i> Clavien–Dindo classification <sup>a</sup> Patients number with and with <sup>b</sup> Complications group vs. contro *More patients in the complicati	of surgical i out concerr l group on group re	complications, ied complicatio sceived adjuva	NOS Newcastle ons int chemothera	e-Ottawa Scale, <i>N</i> Ipy	A not available, <i>NR</i> not r	eported, OS overall surviv	al, <i>RFS</i> recurrence-fre	e survival		

Wang et al. World Journal of Surgical Oncology (2019) 17:52

Page 4 of 10

		Hazard Ratio	Hazard Ratio
Study or Subgroup log[H	lazard Ratio] SE Weight	IV, Random, 95% CI Year	IV, Random, 95% CI
1.1.1 Any reported complica	tions and overall survival		
Tsujimoto H. et al.	0.6313 0.1152 9.7%	1.88 [1.50, 2.36] 2009	-
Sierzega M. et al.	1.1442 0.3735 5.6%	3.14 [1.51, 6.53] 2010	
Yoo HM et al	1 2754 0 228 7 9%	3 58 [2 29 5 60] 2011	
Nagasako V. et al	0.8961 0.4179 5.0%	2 45 [1 08 5 56] 2012	
Nagasako F. et al.	0.0901 0.4179 5.0%		-
Li QG. et al.	0.9163 0.1676 8.9%	2.50 [1.80, 3.47] 2013	
Tokunaga M. et al.	0.8961 0.2572 7.4%	2.45 [1.48, 4.06] 2013	
Kubota T. et al.	0.6313 0.2042 8.3%	1.88 [1.26, 2.81] 2014	
Kim SH. et al.	-0.2107 0.236 7.8%	0.81 [0.51, 1.29] 2015	
Jin LX. et al	0.2624 0.0852 10.1%	1.30 [1.10, 1.54] 2016	-
Climent M et al	-0.3285 0.2873 6.9%	0.72 [0.41 1.26] 2016	
A T M Abdul K et al	0.967 0.2504 7.5%	2 63 [1 61 4 30] 2016	
LiZ ot ol	0.9502 0.2265 6.1%	2.00 [1.01, 4.00] 2010	
LI Z. et al.	0.6502 0.3365 6.1%	2.34 [1.21, 4.53] 2016	
Watanabe M. et al.	-0.0305 0.1738 8.8%	0.97 [0.69, 1.36] 2018	
Subtotal (95% CI)	100.0%	1.79 [1.39, 2.30]	$\bullet$
Heterogeneity: Tau <sup>2</sup> = 0.16; Cl	$hi^2 = 64.62, df = 12 (P < 0.00001);$	l² = 81%	
Test for overall effect. Z = 4.52	2 (F < 0.00001)		
1.1.2 Any reported complica	tions and overall survival (exclu	uding in-hospital mortality)	
Tsujimoto H. et al.	0.6313 0.1152 16.3%	1.88 [1.50, 2.36] 2009	-
Sierzega M. et al	1 1442 0 3735 7 9%	3 14 [1 51 6 53] 2010	
Kubota T, et al	0.6313 0.2042 13.2%	1 88 [1 26 2 81] 2014	
Kim Cl.L. et al.	0.0010 0.2042 10.2%		
	-0.2107 0.236 12.0%		
Climent M. et al.	-0.3285 0.2873 10.3%	0.72 [0.41, 1.26] 2016	
Jin LX. et al	0.2624 0.0852 17.1%	1.30 [1.10, 1.54] 2016	*
Watanabe M. et al.	-0.0305 0.1738 14.3%	0.97 [0.69, 1.36] 2018	+
Li Z. et al.	0.8502 0.3365 8.9%	2.34 [1.21, 4.53] 2018	
Subtotal (95% CI)	100.0%	1.40 [1.06, 1.84]	◆
Hotorogonoity: Tou2 = 0.44: 0	$hi^2 = 21.50 df = 7/D < 0.0001 l^2$	- 70%	•
Test for overall effect: Z = 2.39	P = 0.09, $u = 7 (P < 0.0001)$ ; $P = 0.02$	- / 0 /0	
1.1.3 Infectious complication	ns and overall survival		
Tsujimoto H. et al.	0.6313 0.1152 19.9%	1.88 [1.50, 2.36] 2009	*
Sierzega M. et al.	1.1442 0.3735 12.9%	3.14 [1.51, 6.53] 2010	
Yoo HM et al	1 2754 0 228 17 0%	3 58 [2 29 5 60] 2011	
Tokupaga M. at al	0 9061 0 2572 16 29/	2 45 [1 49 4 06] 2012	
Tokunaga M. et al.	0.0901 0.2572 10.2%	2.45 [1.46, 4.00] 2015	
KIM SH. et al.	-0.2107 0.236 16.8%	0.81 [0.51, 1.29] 2015	
Climent M. et al.	0.1222 0.2229 17.2%	1.13 [0.73, 1.75] 2016	
Subtotal (95% CI)	100.0%	1.86 [1.22, 2.83]	$\bullet$
Heterogeneity: Tau <sup>2</sup> = 0.22: C	$hi^2 = 28.69 df = 5 (P < 0.0001) l^2$	= 83%	
Test for overall effect: $Z = 2.90$	0 (P = 0.004)	0070	
1 1 4 Infectious complication	and overall survival (excludin	in-bospital mortality)	
1.1.4 Infectious complication	ns and overall survival (excludir	ıg in-hospital mortality)	-
1.1.4 Infectious complication Tsujimoto H. et al.	ns and overall survival (excludir 0.6313 0.1152 30.3%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009	•
<b>1.1.4 Infectious complication</b> Tsujimoto H. et al. Sierzega M. et al.	ns and overall survival (excludir 0.6313 0.1152 30.3% 1.1442 0.3735 18.8%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010	•
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al.	ns and overall survival (excludir 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1%	ig in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 (0.51, 1.29) 2015	<b>-</b>
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al.	ns and overall survival (excludir 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.120 (73, 1.75] 2016	
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Climent M. et al.	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.0, 2.49]	
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Climent M. et al. Subtotal (95% CI)	ns and overall survival (excludin 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.229 25.8% 100.0%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40]	<b>*</b>
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; C Tort for event). dfoat: 7 = 1.5:	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> =	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 81%	  ◆
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); I <sup>2</sup> = $\mathfrak{t}$ (P = 0.12)	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 81%	* * *
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication	ns and overall survival (excludii 0.6313 0.1152 $30.3\%$ 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); I <sup>2</sup> = 4 (P = 0.12) rs and overall survival (excludii	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% Ig in-hospital mortality, excluding the study of K	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Climert M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsuiimoto H. et al	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) 15 and overall survival (excludii 0.6313 0.1152 44.2%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 81% 18 [1.50, 2.36] 2009	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al.	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludin 0.6313 0.1152 44.2% 1.1412 0.2375 0.24.9%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 2.4416 4 6 52] 2010	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Cuimert M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al.	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludin 0.6313 0.1152 44.2% 1.1442 0.3735 21.8%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Climent M. et al. Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.19; Cl Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al.	$\label{eq:response} \begin{array}{c} \text{ns and overall survival (excludin } 0.6313 \ 0.1152 \ 30.3\% \\ 1.1442 \ 0.3735 \ 18.8\% \\ -0.2107 \ 0.236 \ 25.1\% \\ 0.1222 \ 0.2229 \ 25.8\% \\ 100.0\% \\ \text{hi}^2 = 15.93, \text{ df} = 3 \ (P = 0.001); \ \text{I}^2 = 4 \ (P = 0.12) \\ \hline \text{ns and overall survival (excludin } 0.6313 \ 0.1152 \ 44.2\% \\ 1.1442 \ 0.3735 \ 21.8\% \\ 0.1222 \ 0.3229 \ 21.8\% \\ 0.1222 \ 0.3229 \ 34.1\% \end{array}$	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% rg in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Cilmert M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; Ci Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Cilment M. et al. Subtotal (95% CI)	$\begin{array}{c} \text{ns and overall survival (excludii}\\ 0.6313  0.1152  30.3\%\\ 1.1442  0.3735  18.8\%\\ -0.2107  0.236  25.1\%\\ 0.1222  0.2229  25.8\%\\ 100.0\%\\ \text{hi}^2 = 15.93, \text{ df = } 3 (\text{P} = 0.001); \text{ I}^2 = 4 (\text{P} = 0.12)\\ \text{ns and overall survival (excludif}\\ 0.6313  0.1152  44.2\%\\ 1.1442  0.3735  21.8\%\\ 0.1222  0.2229  34.1\%\\ 100.0\% \end{array}$	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% 1g in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79]	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Climent M. et al. Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.19; Cl Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.11: Cl	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludii 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 7(10,04); l <sup>2</sup>	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% 1g in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 1%	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Culment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Culment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.44	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludii 0.6313 0.1152 44.2% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 7( 5 (P = 0.01)	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 3%	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Culiment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; Ci Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Culiment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; Ci Test for overall effect: Z = 2.45	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludir 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 7(0.5) 5 (P = 0.01)	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% tg in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 1%	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 <b>1.1.5</b> Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 <b>1.1.6</b> Leakage and overall st	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludir 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 70 5 (P = 0.01) rrvival	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 2%	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Climent M. et al. Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.19; Cl Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.11; Cl Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al.	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludii 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 7( 5 (P = 0.01) Invival 0.6627 0.2202 26.2%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% 1g in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 3%	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. (Kim SH. et al. Culment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al.	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludi 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 7( 5 (P = 0.01) rvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2016 1.77 [1.12, 2.79] 2%	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al.	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludi 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 7( 5 (P = 0.01) rvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 81% ng in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 3% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.9, 5.60] 2011	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. (Kim SH. et al. Culment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Yoo HM. et al.	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludir 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 7( 5 (P = 0.01) rvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2016 1.77 [1.12, 2.79] 2% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.20] 2015	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al. Ciliment M. et al. Subtotal (95% C)) Heterogeneity: Tau <sup>2</sup> = 0.19; Cl Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Subtotal (95% C)) Heterogeneity: Tau <sup>2</sup> = 0.11; Cl Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Kim SH. et al.	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludii 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 0.1222 0.2229 34.1% 1.1422 0.0735 21.8% 1.00.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 7( 5 (P = 0.01) rrvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 3% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; Ci Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; Ci Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Yoo HM. et al. Kim SH. et al.	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludir 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 70 5 (P = 0.01) rvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 2% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00]	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 <b>1.1.5</b> Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 <b>1.1.6</b> Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Yoo HM. et al. Ximoto H. et al. Sierzega M. et al. Yoo HM. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludii 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 70 5 (P = 0.01) Irvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 1.81% ng in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 3% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87%	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.56 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Yoo HM. et al. Sierzega M. et al. Yoo HM. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.05	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludii 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 0.1222 0.2229 34.1% 1.00.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 70 5 (P = 0.01) irvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> l (P = 0.04)	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 1.81% ng in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 3.44 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87%	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Culiment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludi 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 0.1222 0.2229 34.1% 1.1422 0.3735 21.8% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 7( 5 (P = 0.01) rvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> I (P = 0.04) rvival (excluding in-hospital mo	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 3% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87%	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. (Kim SH. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; Ci Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; Ci Test for overall effect: Z = 2.48 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; Ci Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; Ci Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al.	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludir 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 7( 5 (P = 0.01) rrvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 2.58, df = 3 (P < 0.0001); l <sup>2</sup> I (P = 0.04) rrvival (excluding in-hospital mo 0.6627 0.2002 35.7%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] % 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87%	(im SH et al.)
<ul> <li>1.1.4 Infectious complication Tsujimoto H. et al.</li> <li>Sierzega M. et al.</li> <li>Kim SH. et al.</li> <li>Cuiment M. et al.</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: Tau<sup>2</sup> = 0.19; CI</li> <li>Test for overall effect: Z = 1.56</li> <li>1.1.5 Infectious complication</li> <li>Tsujimoto H. et al.</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: Tau<sup>2</sup> = 0.11; CI</li> <li>Test for overall effect: Z = 2.45</li> <li>1.1.6 Leakage and overall su</li> <li>Tsuigmoto H. et al.</li> <li>Sierzega M. et al.</li> <li>Yoo HM. et al.</li> <li>Sierzega M. et al.</li> <li>Yoo HM. et al.</li> <li>Sierzega M. et al.</li> <li>Yoo HM. et al.</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: Tau<sup>2</sup> = 0.42; CI</li> <li>Test for overall effect: Z = 2.07</li> <li>1.1.7 Leakage and overall su</li> <li>Tsujimoto H. et al.</li> </ul>	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludii 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 0.1222 0.2229 34.1% 1.1442 0.3735 21.8% 0.1222 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> I (P = 0.04) Irvival (excluding in-hospital mo 0.6627 0.2202 35.7%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 1.81% ng in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 3% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% prtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87%	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.48 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al.	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludir 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 7( 5 (P = 0.01) rrvial 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% 100.0% hi <sup>2</sup> = 2.58, df = 3 (P < 0.0001); l <sup>2</sup> (P = 0.04) rrvial (excluding in-hospital mo 0.6627 0.2202 35.7% 1.1442 0.3735 29.2%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] % 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% ntality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Yoo HM. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Sierzega M. et al. Sierzega M. et al. Sierzega M. et al.	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludii 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.229 34.1% 0.1222 0.229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 74 5 (P = 0.01) irvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> 1 (P = 0.04) irvival (excluding in-hospital mo 0.6627 0.2202 35.7%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 1.81% ng in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% vrtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2019	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Culiment M. et al. Culiment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; Ci Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; Ci Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; Ci Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; Ci Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Sierzega M. et al. Sierzega M. et al. Sierzega M. et al.	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludir 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 71 5 (P = 0.01) rvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> 1 (P = 0.04) rvival (excluding in-hospital mc 0.6627 0.2202 35.7% 1.1442 0.3735 29.2% -0.2107 0.236 35.1% -0.2107 0.236 35.1%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% vrtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.64 [0.78, 3.46]	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Siorzega M. et al. Yoo HM. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Siorzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Siorzega M. et al. Kim SH. et al. Subtotal (95% CI)	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludii 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 71 5 (P = 0.01) Irvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> 1 (P = 0.04) Irvival (excluding in-hospital mo 0.6627 0.2202 35.7% 100.0% hi <sup>2</sup> = 22.09, df = 2 (P = 0.02).8 -0.2107 0.236 35.1% 100.0%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 81% ng in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% wrtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2019 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.64 [0.78, 3.46] 83%	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Culiment M. et al. Culiment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.47 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.36; CI Heterogeneity: Tau <sup>2</sup> = 0.36; CI Heterogeneily: Tau <sup>2</sup> = 0.36; CI Heterogeneily: Tau <sup>2</sup> = 0.36; CI	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludi 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 0.1222 0.2229 34.1% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 1.1442 0.3735 21.8% 0.1222 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.001); l <sup>2</sup> 1 (P = 0.04) rrvival (excluding in-hospital mo 0.6627 0.2202 35.7% 1.1442 0.3735 29.2% -0.2107 0.236 35.1% 100.0% hi <sup>2</sup> = 12.09, df = 2 (P = 0.002); l <sup>2</sup> = 1 (P = 0.9)	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 81% ng in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% prtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.64 [0.78, 3.46] 83%	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Culiment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; Ci Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Culiment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; Ci Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; Ci Test for overall effect: Z = 2.42; 1.1.7 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; Ci Test for overall effect: Z = 2.02; Li, Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.36; Ci Test for overall effect: Z = 1.37; No overall effect: Z = 2.37; No overall effect: Z = 2.37; No overall effect: Z = 2.37; No overall e	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludir 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 71 5 (P = 0.01) rrvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% 0.2627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> 1 (P = 0.04) rrvival (excluding in-hospital mc 0.6627 0.2202 35.7% 1.1442 0.3735 29.2% -0.2107 0.236 35.1% 100.0% hi <sup>2</sup> = 12.09, df = 2 (P = 0.002); l <sup>2</sup> = 1 1 (P = 0.19)	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.56 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% prtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.64 [0.78, 3.46] 83%	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al.	ns and overall survival (excludin 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludin 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 71 5 (P = 0.01) rrvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> 1 (P = 0.04) rrvival (excluding in-hospital mc 0.6627 0.2202 35.7% 1.1442 0.3735 29.2% -0.2107 0.236 35.1% 100.0% hi <sup>2</sup> = 12.09, df = 2 (P = 0.002); l <sup>2</sup> = l (P = 0.19) rrvival (excluding in-hospital mc	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 20% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% prtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.64 [0.78, 3.46] 83%	Sim SH et al.)
<ul> <li>1.1.4 Infectious complication Tsujimoto H. et al.</li> <li>Sierzega M. et al.</li> <li>Kim SH. et al.</li> <li>Ciliment M. et al.</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: Tau<sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54</li> <li>1.1.5 Infectious complication Tsujimoto H. et al.</li> <li>Sierzega M. et al.</li> <li>Ciliment M. et al.</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: Tau<sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.44</li> <li>1.1.6 Leakage and overall su Tsujimoto H. et al.</li> <li>Sierzega M. et al.</li> <li>Sierzega M. et al.</li> <li>Sierzega M. et al.</li> <li>Sierzega M. et al.</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: Tau<sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07</li> <li>1.1.7 Leakage and overall su Tsujimoto H. et al.</li> <li>Sierzega M. et al.</li> <li>Sierzega M. et al.</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: Tau<sup>2</sup> = 0.36; CI Test for overall effect: Z = 1.37</li> <li>1.1.8 Leakage and overall su Tsujimoto H. et al.</li> </ul>	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludin 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.229 34.1% 0.1222 0.229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 71 5 (P = 0.01) irvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> 1 (P = 0.04) irvival (excluding in-hospital mo 0.6627 0.2202 35.7% 1.1442 0.3735 29.2% -0.2107 0.236 55.1% 100.0% hi <sup>2</sup> = 12.09, df = 2 (P = 0.002); l <sup>2</sup> = 1 (P = 0.9) irvival (excluding in-hospital mo 0.6627 0.2202 69.6%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% rg in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% rrtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.64 [0.78, 3.46] 83% rrtality, excluding the study of Kim SH et al.) 1.94 [1.26, 2.99] 2009	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Cilment M. et al. Cilment M. et al. Culment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; Ci Test for overall effect: Z = 1.5 <sup>2</sup> 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Cilment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; Ci Test for overall effect: Z = 2.42 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; Ci Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.36; Ci Test for overall effect: Z = 1.37 1.1.8 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al.	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludir 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 71 5 (P = 0.01) rrvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 2.58, df = 3 (P < 0.0001); l <sup>2</sup> 1 (P = 0.04) rrvival (excluding in-hospital mo 0.6627 0.2202 35.7% 1.1442 0.3735 29.2% -0.2107 0.236 35.1% 1.00.0% hi <sup>2</sup> = 12.09, df = 2 (P = 0.002); l <sup>2</sup> = 1 (P = 0.19) rrvival (excluding in-hospital mo 0.6627 0.2202 69.6%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% prtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.64 [0.78, 3.46] 83%	(im SH et al.)
<ul> <li>1.1.4 Infectious complication Tsujimoto H. et al.</li> <li>Sierzega M. et al.</li> <li>Cuiment M. et al.</li> <li>Cuiment M. et al.</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: Tau<sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54</li> <li>1.1.5 Infectious complication Tsujimoto H. et al.</li> <li>Sierzega M. et al.</li> <li>Cuiment M. et al.</li> <li>Sierzega M. et al.</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: Tau<sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45</li> <li>1.1.6 Leakage and overall su Tsujimoto H. et al.</li> <li>Sierzega M. et al.</li> <li>Yoo HM. et al.</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: Tau<sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07</li> <li>1.1.7 Leakage and overall su Tsujimoto H. et al.</li> <li>Sierzega M. et al.</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: Tau<sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07</li> <li>1.1.7 Leakage and overall su Tsujimoto H. et al.</li> <li>Sierzega M. et al.</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: Tau<sup>2</sup> = 0.36; CI Test for overall effect: Z = 1.37</li> <li>1.1.8 Leakage and overall su Tsujimoto H. et al.</li> <li>Sierzega M. et al.</li> <li>Siuptotal (95% CI)</li> </ul>	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludin 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 7h 5 (P = 0.01) irvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> 1 (P = 0.04) irvival (excluding in-hospital mo 0.6627 0.2202 35.7% 100.0% hi <sup>2</sup> = 12.09, df = 2 (P = 0.002); l <sup>2</sup> = 1 (P = 0.9) irvival (excluding in-hospital mo 0.6627 0.2202 69.6% 1.1442 0.3735 30.4%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% xtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.64 [0.78, 3.46] 83% xtality, excluding the study of Kim SH et al.) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 2.25 [1.45, 3.47]	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Culiment M. et al. Culiment M. et al. Subtotal (95% C) Heterogeneity: Tau <sup>2</sup> = 0.19; Ci Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Subtotal (95% C) Heterogeneity: Tau <sup>2</sup> = 0.11; Ci Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% C) Heterogeneity: Tau <sup>2</sup> = 0.42; Ci Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Subtotal (95% C) Heterogeneity: Tau <sup>2</sup> = 0.42; Ci Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Subtotal (95% C) Heterogeneity: Tau <sup>2</sup> = 0.36; Ci Test for overall effect: Z = 1.37 1.1.8 Leakage and overall su Tsujimoto H. et al. Subtotal (95% C) Heterogeneity: Tau <sup>2</sup> = 0.36; Ci Test for overall effect: Z = 1.37 1.1.8 Leakage and overall su Tsujimoto H. et al. Subtotal (95% C)	ns and overall survival (excludii 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludii 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 71 5 (P = 0.01) rrvial 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% 100.0% hi <sup>2</sup> = 2.58, df = 3 (P < 0.0001); l <sup>2</sup> 1 (P = 0.04) rrvial (excluding in-hospital mo 0.6627 0.2202 35.7% 1.1442 0.3735 29.2% -0.2107 0.236 35.1% 100.0% hi <sup>2</sup> = 12.09, df = 2 (P = 0.002); l <sup>2</sup> = 1 (P = 0.19) rrvial (excluding in-hospital mo 0.6627 0.2202 35.7% 1.1442 0.3735 30.4% 100.0%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 1.81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% prtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.64 [0.78, 3.46] *83% rrtality, excluding the study of Kim SH et al.) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 2.25 [1.45, 3.47]	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.36; CI Test for overall effect: Z = 1.37 1.1.8 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Simono H. et al. Simono H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.36; CI Test for overall effect: Z = 1.37 1.1.8 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Simono H. et al. Sierzega M. et al. Simono H. et al. Sierzega M. et al. Sierzega	ns and overall survival (excludin 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludin 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 0.1222 0.2229 34.1% 0.1222 0.2229 34.1% 0.1222 0.2229 34.1% 0.1222 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> = 1 1 (P = 0.04) Irvival (excluding in-hospital mc 0.6627 0.2202 35.7% 100.0% hi <sup>2</sup> = 12.09, df = 2 (P = 0.002); l <sup>2</sup> = 1 1 (P = 0.19) Irvival (excluding in-hospital mc 0.6627 0.2202 69.6% 1.1442 0.3735 30.4% 100.0%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] 81% ng in-hospital mortality, excluding the study of K 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% rtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.64 [0.78, 3.46] *83% rtality, excluding the study of Kim SH et al.) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 2.25 [1.45, 1.653] 2010 2.25 [1.45, 3.47] %	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Ciliment M. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.45 1.1.7 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Sibutotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.36; CI Test for overall effect: Z = 1.37 1.1.8 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.36; CI Test for overall effect: Z = 1.37 1.1.8 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.29; CI Test for overall effect: Z = 0.02; CI Test for o	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludir 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 70 5 (P = 0.01) rrvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> 1 (P = 0.04) rrvival (excluding in-hospital mc 0.6627 0.2202 35.7% 1.1442 0.3735 29.2% -0.2107 0.236 35.1% 100.0% hi <sup>2</sup> = 12.09, df = 2 (P = 0.022); l <sup>2</sup> = 1 1 (P = 0.19) rrvival (excluding in-hospital mc 0.6627 0.2202 69.6% 1.1442 0.3735 30.4% 100.0%	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% xrtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 2.83% xrtality, excluding the study of Kim SH et al.) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 2.25 [1.45, 3.47] 3%	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Culment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; Ci Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; Ci Test for overall effect: Z = 2.42 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; Ci Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; Ci Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.36; Ci Test for overall effect: Z = 1.37 1.1.8 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.36; Ci Test for overall effect: Z = 3.67 Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.02; Ci Test for overall effect: Z = 3.67 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.02; Ci Test for overall effect: Z = 3.67 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.02; Ci Test for overall effect: Z = 3.67 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.02; Ci Test for overall effect: Z = 3.67 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.02; Ci Test for overall effect: Z = 3.67 Subtotal (95% CI)	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludir 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 71 5 (P = 0.01) rrvival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 2.58, df = 3 (P < 0.0001); l <sup>2</sup> 1 (P = 0.04) rrvival (excluding in-hospital mo 0.6627 0.2202 35.7% 1.1442 0.3735 29.2% -0.2107 0.236 35.1% 1.00.0% hi <sup>2</sup> = 12.09, df = 2 (P = 0.002); l <sup>2</sup> = 1 1 (P = 0.19) rrvival (excluding in-hospital mo 0.6627 0.2202 69.6% 1.1442 0.3735 30.4% 100.0% hi <sup>2</sup> = 1.23, df = 1 (P = 0.27); l <sup>2</sup> = 15 5 (P = 0.0003)	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% prtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.64 [0.78, 3.46] *83% rrtality, excluding the study of Kim SH et al.) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 2.25 [1.45, 3.47] 3%	(im SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; Cl Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Climent M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; Cl Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; Cl Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; Cl Test for overall effect: Z = 2.07 1.1.7 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.36; Cl Test for overall effect: Z = 1.37 1.1.8 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.02; Cl Test for overall effect: Z = 3.67 1.1.8 Leakage and overall su Tsujimoto H. et al. Sierzega M. et al. Subtotal (95% CI)	ns and overall survival (excludin 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludin 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 71 5 (P = 0.01) invival 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% -0.2107 0.236 25.8% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> = 1 1 (P = 0.04) invival (excluding in-hospital mc 0.6627 0.2202 35.7% 100.0% hi <sup>2</sup> = 12.09, df = 2 (P = 0.002); l <sup>2</sup> = 1 1 (P = 0.19) invival (excluding in-hospital mc 0.6627 0.2202 95.6% 1.1442 0.3735 30.4% 100.0% hi <sup>2</sup> = 1.23, df = 1 (P = 0.27); l <sup>2</sup> = 19 5 (P = 0.0003)	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of P 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% rtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.64 [0.78, 3.46] *83% rtality, excluding the study of Kim SH et al.) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 2.25 [1.45, 3.47] 3%	Sim SH et al.)
1.1.4 Infectious complication Tsujimoto H. et al. Sierzega M. et al. Ciliment M. et al. Ciliment M. et al. Ciliment M. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.19; CI Test for overall effect: Z = 1.54 1.1.5 Infectious complication Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.11; CI Test for overall effect: Z = 2.45 1.1.6 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.05 1.1.7 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.42; CI Test for overall effect: Z = 2.05 1.1.7 Leakage and overall su Tsujimoto H. et al. Sibutotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.36; CI Test for overall effect: Z = 1.37 1.1.8 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.36; CI Test for overall effect: Z = 1.37 1.1.8 Leakage and overall su Tsujimoto H. et al. Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.25; CI Test for overall effect: Z = 3.65 Network and the tal. Subtotal (95% CI)	ns and overall survival (excludi 0.6313 0.1152 30.3% 1.1442 0.3735 18.8% -0.2107 0.236 25.1% 0.1222 0.2229 25.8% 100.0% hi <sup>2</sup> = 15.93, df = 3 (P = 0.001); l <sup>2</sup> = 4 (P = 0.12) ns and overall survival (excludir 0.6313 0.1152 44.2% 1.1442 0.3735 21.8% 0.1222 0.2229 34.1% 100.0% hi <sup>2</sup> = 6.68, df = 2 (P = 0.04); l <sup>2</sup> = 70 5 (P = 0.01) <i>irvival</i> 0.6627 0.2202 26.2% 1.1442 0.3735 21.9% 1.2754 0.228 26.0% 100.0% hi <sup>2</sup> = 22.58, df = 3 (P < 0.0001); l <sup>2</sup> 1 (P = 0.04) <i>irvival</i> (excluding in-hospital mc 0.6627 0.2202 35.7% 1.1442 0.3735 29.2% -0.2107 0.236 35.1% 100.0% hi <sup>2</sup> = 12.09, df = 2 (P = 0.002); l <sup>2</sup> = 1 1 (P = 0.19) <i>irvival</i> (excluding in-hospital mc 0.6627 0.2202 69.6% 1.1442 0.3735 30.4% 100.0% hi <sup>2</sup> = 1.23, df = 1 (P = 0.27); l <sup>2</sup> = 15 5 (P = 0.0003)	ng in-hospital mortality) 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.13 [0.73, 1.75] 2016 1.47 [0.90, 2.40] *81% ng in-hospital mortality, excluding the study of M 1.88 [1.50, 2.36] 2009 3.14 [1.51, 6.53] 2010 1.13 [0.73, 1.75] 2016 1.77 [1.12, 2.79] 0% 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 3.58 [2.29, 5.60] 2011 0.81 [0.51, 1.29] 2015 2.02 [1.02, 4.00] = 87% xrtality) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 0.81 [0.51, 1.29] 2015 1.84 [0.78, 3.46] *83% xrtality, excluding the study of Kim SH et al.) 1.94 [1.26, 2.99] 2009 3.14 [1.51, 6.53] 2010 2.25 [1.45, 3.47] 3%	Sim SH et al.)



analysis [10, 11, 20]. The pooled HR for the RFS in the infectious complications group was 1.65 (1.25, 2.18) and was 1.46 (1.05, 2.03) after excluding the in-hospital mortality (Fig. 4). The results of the sensitivity analysis demonstrated that no individual study significantly influenced the overall effect of HRs.

# Studies on postoperative complications and survival in separated pathological stages

Three studies analyzed the correlations between postoperative complications and prognosis in stage I gastric cancer [13, 18, 19]. One study reported a nonsignificant correlation between postoperative complications and OS but did not present any detailed data or figures in the published report [18]. Therefore, two studies with available data were included in the analysis [13, 19]. The pooled HR (95% CI) of postoperative complications for OS in patients with stage I gastric cancer was 2.39 (0.77, 7.46) (Fig. 5).

Three studies analyzed the correlation between postoperative complications and OS in stage II gastric cancer [13, 18, 19]. The pooled HR of postoperative complications for OS in patients with stage II gastric cancer was 4.35 (2.58, 7.35) (Fig. 5).

Three studies analyzed the correlation between postoperative complications and OS in patients with stage III gastric cancer [13, 18, 19], and two studies reported the RFS [18, 20]. The pooled HR of postoperative complications for OS in patients with stage III gastric cancer from was 2.84 (1.77, 4.56), and the pooled HR (95% CI) for RFS was 3.86 (1.85, 8.05) (Fig. 5).

# Discussion

The present study undertook a comprehensive review and meta-analysis of the literatures to assess the relationship between postoperative complications and patient prognosis. The results demonstrated that, although the correlation was not found by several studies, the pooled results showed that postoperative complications correlated with poor prognosis.

Several reasons may contribute to the divergences. First, the negative findings in some studies may be ascribed to the interfered application of adjuvant chemotherapy. Jin et al. demonstrated lower proportion of adjuvant chemotherapy in the complication group (47% vs. 61%), and the combination of postoperative complications and receiving no adjuvant therapy significantly increased the hazard of death and recurrence. Furthermore, decreased OS and RFS were not observed in patients who experienced complications but received adjuvant therapy [21]. Another study demonstrated that the adjuvant chemotherapy was postponed in patients with intra-abdominal complications  $(55.3 \pm 34.7 \text{ vs. } 26.6 \pm 11.9 \text{ days})$  [22], and the postponed chemotherapy is correlated with poorer survival in patients with gastric cancer [28]. Second, the application of prophylactic neoadjuvant chemotherapy may abolish the poor prognosis induced by postoperative complications. In a cohort with 101 patients who underwent curative gastrectomy after receiving neoadjuvant chemotherapy, Eto et al. demonstrated a comparable RFS between patients with and without postoperative complications, and the 5-year RFS was 41.7% and 43.9%, respectively [11]. Third, the varied perioperative stress level may be an additional reason for the negative finding. Saito et al. demonstrated

			Hazard Ratio		Hazard Ratio
Study or Subgroup log[	Hazard Ratio] S	E Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% Cl
2.1.1 Any reported complic	ations and RFS				
Tokunaga M. et al.	0.7975 0.261	4 9.1%	2.22 [1.33, 3.71]	2013	
Saito T. et al.	0.0953 0.230	6 11.7%	1.10 [0.70, 1.73]	2015	· · · · · · · · · · · · · · · · · · ·
Hayashi T. et al.	0.6729 0.27	2 8.4%	1.96 [1.15, 3.34]	2015	
Jin LX. et al	0.2624 0.128	37.5%	1.30 [1.01, 1.67]	2016	
Climent M. et al.	-0.0101 0.358	4.8%	0.99 [0.49, 2.00]	2016	· · · · · · · · · · · · · · · · · · ·
Eto K. et al.	0.1655 0.288	88 7.5%	1.18 [0.67, 2.08]	2018	
Watanabe M. et al.	-0.0202 0.171	7 21.1%	0.98 [0.70, 1.37]	2018	
Subtotal (95% CI)		100.0%	1.28 [1.10, 1.49]		$\bullet$
Heterogeneity: Chi <sup>2</sup> = 10.35,	df = 6 (P = 0.11); l <sup>2</sup> =	42%			
Test for overall effect: Z = 3.1	12 (P = 0.002)				
2.1.2 Any reported complic	ations and RFS (ex	cluding in-h	ospital mortality) )		
Hayashi T. et al.	0.6729 0.27	2 14.4%	1.96 [1.15, 3.34]	2015	;
Climent M. et al.	-0.0101 0.358	88 8.3%	0.99 [0.49, 2.00]	2016	· · · · · · · · · · · · · · · · · · ·
Jin LX. et al	0.2624 0.128	64.4%	1.30 [1.01, 1.67]	2016	
Eto K. et al.	0.1655 0.288	12.8%	1.18 [0.67, 2.08]	2018	· · · · · · · · · · · · · · · · · · ·
Subtotal (95% CI)		100.0%	1.33 [1.09, 1.63]		◆
Heterogeneity: Chi <sup>2</sup> = 2.91, d	$f = 3 (P = 0.41); I^2 = 9$	0%			
Test for overall effect: Z = 2.7	′7 (P = 0.006)				
2.1.3 Infectious complication	ons and RFS				
Tokunaga M. et al.	0.7975 0.261	4 29.5%	2.22 [1.33, 3.71]	2013	,
Hayashi T. et al.	0.6729 0.27	2 27.3%	1.96 [1.15, 3.34]	2015	;
Climent M. et al.	0.207 0.302	24 22.0%	1.23 [0.68, 2.22]	2016	;
Eto K. et al.	0.174 0.308	35 21.2%	1.19 [0.65, 2.18]	2018	
Subtotal (95% CI)		100.0%	1.65 [1.25, 2.18]		
Heterogeneity: Chi <sup>2</sup> = 3.75, d	f = 3 (P = 0.29); l <sup>2</sup> = 2	20%			
Test for overall effect: Z = 3.5	53 (P = 0.0004)				
2.1.4 Infectious complication	ons and RFS (exclue	ding in-hos	oital mortality)		
Havashi T. et al.	0.6729 0.27	2 38.7%	1.96 [1.15, 3.34]	2015	;
Climent M. et al.	0.207 0.302	4 31.3%	1.23 [0.68, 2.22]	2016	
Eto K. et al.	0.174 0.308	35 30.1%	1.19 [0.65, 2.18]	2018	
Subtotal (95% CI)		100.0%	1.46 [1.05, 2.03]		
Heterogeneity: $Chi^2 = 1.93$ , d	$f = 2 (P = 0.38);  ^2 = 6$	0%	-		
Test for overall effect: Z = 2.2	23 (P = 0.03)				
					U.2 U.3 I 2 3
Fig. 4 The association of posto	operative complication	ns with recu	Irrence-free survival		

that the postoperative inflammation degree (reflected by the CRP level), rather than the postoperative complication itself, is related to the recurrence and poor prognosis [9]. Besides, Watanabe et al. also demonstrated comparable prognosis between patients with and without postoperative complications [12]. Their patients underwent total gastrectomy with splenectomy for the treatment of proximal advanced gastric cancer. The extensive resection might lead to an excessive surgical stress in both groups and that may lead to a deteriorated prognosis in patients without postoperative complications [29].

Accordingly, the results of the present study may highlight the importance of both adjuvant and neoadjuvant chemotherapy in patients with postoperative complications or with a high risk of developing postoperative complications. The results of the present study may have also highlighted the stress control management during the perioperative period. However, whether a decreased stress level will result to an improved prognosis remains to be determined. Additionally, any other methods that decrease the postoperative complications may also indirectly improve the prognosis. The intraoperative manipulation, such as the choice of reconstruction or the less invasive approach, may play a role in decreasing the postoperative complications and thereby improve the prognosis indirectly. For instance, recent studies demonstrated that BI reconstruction method significantly reduced the postoperative complications after laparoscopic distal gastrectomy [30, 31]. Therefore, patients may benefit more from that approach with low risk of postoperative complications.

In the analysis of the relationship between infectious complications or gastrointestinal leakages and OS, the study from Kim et al. demonstrated high heterogeneity.

			Hazard Ratio		Hazard Ratio
Study or Subgroup log	[Hazard Ratio]	SE Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
3.1.1 Overall survival of sta	age I				
Tsujimoto H. et al.	0.4824 0.3	291 68.9%	1.62 [0.85, 3.09]	2009	+∎-
Kubota T. et al.	1.7352 0.8	367 31.1%	5.67 [1.10, 29.23]	2014	
Subtotal (95% CI)		100.0%	2.39 [0.77, 7.46]		
Heterogeneity: Tau <sup>2</sup> = 0.38;	Chi <sup>2</sup> = 1.94, df = 1 (	P = 0.16); I <sup>2</sup> =	48%		
Test for overall effect: Z = 1.	50 (P = 0.13)				
3.1.2 Overall survival of sta	age II				
Tsujimoto H. et al.	1.4183 0.3	054 76.6%	4.13 [2.27, 7.51]	2009	-∎-
Tokunaga M. et al.	1.662 0.	755 12.5%	5.27 [1.20, 23.14]	2013	
Kubota T. et al.	1.6174 0.8	101 10.9%	5.04 [1.03, 24.66]	2014	
Subtotal (95% CI)		100.0%	4.35 [2.58, 7.35]		•
Heterogeneity: Tau <sup>2</sup> = 0.00;	Chi <sup>2</sup> = 0.13, df = 2 (	P = 0.94); I <sup>2</sup> =	0%		
Test for overall effect: Z = 5.	50 (P < 0.00001)				
3.1.3 Overall survival of sta	age III				
Tsujimoto H. et al.	0.8198 0.2	013 48.1%	2.27 [1.53, 3.37]	2009	-
Tokunaga M. et al.	1.8116 0.4	776 18.8%	6.12 [2.40, 15.61]	2013	
Kubota T. et al.	0.9361 0.3	096 33.0%	2.55 [1.39, 4.68]	2014	
Subtotal (95% CI)		100.0%	2.84 [1.77, 4.56]		•
Heterogeneity: Tau <sup>2</sup> = 0.08;	Chi <sup>2</sup> = 3.67, df = 2 (	P = 0.16); l <sup>2</sup> =	46%		
Test for overall effect: Z = 4.	34 (P < 0.0001)				
3.1.4 Recurrence free surv	ival of Stage III				
Tokunaga M. et al.	1.3271 0.3	858 94.8%	3.77 [1.77, 8.03]	2013	
Hayashi T. et al.	1.7664 1.6	511 5.2%	5.85 [0.23, 148.78]	2015	
Subtotal (95% CI)		100.0%	3.86 [1.85, 8.05]		-
Heterogeneity: Tau <sup>2</sup> = 0.00;	Chi <sup>2</sup> = 0.07, df = 1 (	P = 0.80); I <sup>2</sup> =	0%		
Test for overall effect: Z = 3.	59 (P = 0.0003)				
					0.01 0.1 1 10 100
					Favours complications Favours control
Fig. 5 The association of post	toperative complica	ations with ov	erall survival and recu	rrence-fi	ree survival within varied pathological stages

Kim et al. found that gastrointestinal leakage was not associated with decreased survival. There are some possible reasons for the negative results [8]. First, the effect of leakage may be diluted by the effect of other complications occurred in the control group. That is to say, other complications other than gastrointestinal leakage may also contribute to the poor prognosis and that may cause an underestimated effect of leakage on prognosis. Second, the sample size may not be adequate to detect the significant correlation because their Kaplan-Meier curve demonstrated a trend of poor OS in the leakage group (p = 0.076) [8].

The present study had some limitations. First, five of the included studies did not exclude in-hospital death in the survival analysis [15–18, 22]. It is well acknowledged that in-hospital mortality would be higher in patients with postoperative complications and would decrease the OS accordingly. Therefore, a subgroup analysis with the eight reports that excluded in-hospital death or have no in-hospital death was performed and a similar result was found (HR 1.40, 95% CI 1.06–1.84). Second, more preoperative comorbidity, a higher ASA or ECOG score, and older age were frequently observed in the complication group, as shown in Additional file 1: Table S1, and such characteristics are correlated with a shorter life expectancy after surgery. As a result, we analyzed the data from seven studies that reported RFS [9–12, 18, 20, 21], and the HR demonstrated a positive correlation between postoperative complications and reduced RFS (HR 1. 28, 95% CI 1.10-1.49). The correlation between postoperative complications and poor RFS still exist after the in-hospital mortality were excluded (HR 1.33, 95% CI 1.09–1.63). Third, patients in the complication group frequently had more advanced disease. Eleven of the studies demonstrated the proportion of each stage, and six of the studies reported comparable stages between the two groups [10–12, 15, 22, 23]. Such a bias may cause an overestimated correlation of postoperative complications with long-term prognosis. To avoid the influence of unbalanced tumor stages, the correlations between complications and prognosis were analyzed in separate stages based on the data from four studies [13, 18-20]. In addition to the correlation between postoperative complications and decreased OS and RFS in stage II and III patients, attention should be paid to stage I patients with postoperative complications because of the undetermined result (Fig. 5). If such a correlation did exist, the application of adjuvant chemotherapy might be expanded to

stage I patients who have developed postoperative complications. However, a limited number of studies were included in the subgroup analysis of separated pathological stages and the confounders cannot be avoided in the subgroup analysis. More solid evidence from studies with larger sample sizes is warranted, and RFS analysis should also be considered in further studies.

# Conclusions

In summary, there is good evidence to support the correlations between postoperative complications and poor prognosis after radical gastrectomy. The influence of postoperative complications on prognosis is also demonstrated in patients with stage II and III gastric cancer but remains to be determined in patients with stage I gastric cancer. To reduce the negative impact of postoperative complications on the long term prognosis, neoadjuvant chemotherapy may be considered in patients with high risk of developing postoperative complications and adjuvant chemotherapy should be enforced in patients who have developed postoperative complications. Additionally, perioperative stress control management might be beneficial for improving the long term prognosis after radical gastrectomy.

# Additional file

Additional file 1: Table S1. NOS of Cohort studies. NOS of Case-control studies. (DOCX 27 kb)

## Abbreviations

HR: Hazard ratio; OS: Overall survival; RFS: Recurrence free survival

#### Acknowledgements

Not applicable

#### Funding

This work was supported by the National Natural Science Foundation of China (grant number 81400662) and Social Development Fund of Shaanxi Province (grant number 2018SF-271)

#### Availability of data and materials

All data generated or analyzed during this study are included in the published articles which were listed in Table 1.

#### Authors' contributions

SW and JY contributed to the study concept and design. LX, QW, JL, ZL, XW, PY, BB, and XL contributed to the acquisition of data. SW, JY, JL, ZL, LX, and QW contributed to the analysis and interpretation of data. LX, SW, JL, XW, and PY contributed to the drafting of the manuscript. QW, JY, BB, and XL contributed to the critical revision of the manuscript for important intellectual content. SW, QW, JL, and ZL contributed to the statistical analysis. SW and JY obtained funding. All authors read and approved the final manuscript.

#### Ethics approval and consent to participate

All analyses were based on previous published studies, thus no ethical approval and patient consent are required.

#### Consent for publication

Not applicable

#### **Competing interests**

The authors declare that they have no competing interests.

## **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Received: 7 December 2018 Accepted: 11 March 2019 Published online: 18 March 2019

#### References

- Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, van Elk P, Obertop H, Gouma DJ, Taat CW, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345:745–8.
- Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347:995–9.
- Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A, Kurita A, Gastric Cancer surgery study Group of Japan Clinical Oncology G. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg. 2005;92: 1103–9.
- Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg. 2005;92:1099–102.
- Yasunaga H, Horiguchi H, Kuwabara K, Matsuda S, Fushimi K, Hashimoto H, Ayanian JZ. Outcomes after laparoscopic or open distal gastrectomy for early-stage gastric cancer: a propensity-matched analysis. Ann Surg. 2013; 257:640–6.
- Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, Ryu SW, Cho GS, Song KY, Ryu SY. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol. 2014;32:627–33.
- Yu J, Hu J, Huang C, Ying M, Peng X, Wei H, Jiang Z, Du X, Liu Z, Liu H, et al. The impact of age and comorbidity on postoperative complications in patients with advanced gastric cancer after laparoscopic D2 gastrectomy: results from the Chinese laparoscropic gastrointestinal surgery study (CLASS) group. Eur J Surg Oncol. 2013;39:1144–9.
- Kim SH, Son SY, Park YS, Ahn SH, Park DJ, Kim HH. Risk factors for anastomotic leakage: a retrospective cohort study in a single gastric surgical unit. J Gastric Cancer. 2015;15:167–75.
- Saito T, Kurokawa Y, Miyazaki Y, Makino T, Takahashi T, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y. Which is a more reliable indicator of survival after gastric cancer surgery: postoperative complication occurrence or C-reactive protein elevation? J Surg Oncol. 2015;112:894–9.
- Climent M, Hidalgo N, Vidal O, Puig S, Iglesias M, Cuatrecasas M, Ramon JM, Garcia-Albeniz X, Grande L, Pera M. Postoperative complications do not impact on recurrence and survival after curative resection of gastric cancer. Eur J Surg Oncol. 2016;42:132–9.
- Eto K, Hiki N, Kumagai K, Shoji Y, Tsuda Y, Kano Y, Yasufuku I, Okumura Y, Tsujiura M, Ida S, et al. Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. Gastric Cancer. 2018;21:703–9.
- 12. Watanabe M, Kinoshita T, Tokunaga M, Kaito A, Sugita S. Complications and their correlation with prognosis in patients undergoing total gastrectomy with splenectomy for treatment of proximal advanced gastric cancer. Eur J Surg Oncol. 2018;44:1181–5.
- Tsujimoto H, Ichikura T, Ono S, Sugasawa H, Hiraki S, Sakamoto N, Yaguchi Y, Yoshida K, Matsumoto Y, Hase K. Impact of postoperative infection on long-term survival after potentially curative resection for gastric cancer. Ann Surg Oncol. 2009;16:311–8.
- Sierzega M, Kolodziejczyk P, Kulig J. Impact of anastomotic leakage on longterm survival after total gastrectomy for carcinoma of the stomach. Br J Surg. 2010;97:1035–42.
- Yoo HM, Lee HH, Shim JH, Jeon HM, Park CH, Song KY. Negative impact of leakage on survival of patients undergoing curative resection for advanced gastric cancer. J Surg Oncol. 2011;104:734–40.
- Nagasako Y, Satoh S, Isogaki J, Inaba K, Taniguchi K, Uyama I. Impact of anastomotic complications on outcome after laparoscopic gastrectomy for early gastric cancer. Br J Surg. 2012;99:849–54.

- Li QG, Li P, Tang D, Chen J, Wang DR. Impact of postoperative complications on long-term survival after radical resection for gastric cancer. World J Gastroenterol. 2013;19:4060–5.
- Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013;20:1575–83.
- Kubota T, Hiki N, Sano T, Nomura S, Nunobe S, Kumagai K, Aikou S, Watanabe R, Kosuga T, Yamaguchi T. Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol. 2014;21:891–8.
- Hayashi T, Yoshikawa T, Aoyama T, Hasegawa S, Yamada T, Tsuchida K, Fujikawa H, Sato T, Ogata T, Cho H, et al. Impact of infectious complications on gastric cancer recurrence. Gastric Cancer. 2015;18:368–74.
- Jin LX, Sanford DE, Squires MH 3rd, Moses LE, Yan Y, Poultsides GA, Votanopoulos KI, Weber SM, Bloomston M, Pawlik TM, et al. Interaction of postoperative morbidity and receipt of adjuvant therapy on long-term survival after resection for gastric adenocarcinoma: results from the U.S. Gastric Cancer Collaborative. Ann Surg Oncol. 2016;23:2398–408.
- Abdul Kader ATM, Murakami Y, Yoshimoto M, Onishi K, Kuroda H, Matsunaga T, Fukumoto Y, Takano S, Tokuyasu N, Osaki T, et al. Intraabdominal complications after curative gastrectomies worsen prognoses of patients with stage II–III gastric cancer. Yonago Acta Medica. 2016;59:210–6.
- Li Z, Bai B, Zhao Y, Yu D, Lian B, Liu Y, Zhao Q. Severity of complications and long-term survival after laparoscopic total gastrectomy with D2 lymph node dissection for advanced gastric cancer: a propensity score-matched, case-control study. Int J Surg. 2018;54:62–9.
- 24. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
- The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [http://www.ohri.ca/programs/ clinical\_epidemiology/oxford.asp].
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9 W264.
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.
- Qu JL, Qu XJ, Li X, Zhang JD, Teng YE, Jin B, Zhao MF, Yu P, Liu J, Li DY, Liu YP. Early initiation of fluorouracil-based adjuvant chemotherapy improves survival in patients with resectable gastric cancer. J BUON. 2015;20:800–7.
- O'Leary DP, Wang JH, Cotter TG, Redmond HP. Less stress, more success? Oncological implications of surgery-induced oxidative stress. Gut. 2013;62:461–70.
- Kim MS, Kwon Y, Park EP, An L, Park H, Park S. Revisiting laparoscopic reconstruction for Billroth 1 versus Billroth 2 versus Roux-en-Y after distal gastrectomy: a systematic review and meta-analysis in the modern era. World J Surg. 2019. https://doi.org/10.1007/s00268-019-04943-x. [Epub ahead of print] PMID: 30756163.
- Watanabe Y, Watanabe M, Suehara N, Saimura M, Mizuuchi Y, Nishihara K, Iwashita T, Nakano T. Billroth-I reconstruction using an overlap method in totally laparoscopic distal gastrectomy: propensity score matched cohort study of short- and long-term outcomes compared with Roux-en-Y reconstruction. Surg Endosc. 2019. https://doi.org/10.1007/s00464-019-06688-z. [Epub ahead of print]PMID: 30758666

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

